Gaye, B.
Prugger, C.
Perier, M. C.
Thomas, F.
Plichart, M.
Guibout, C.
Lemogne, C.
Pannier, B.
Boutouyrie, P.
Jouven, X.
Empana, J. P.
Article History
Received: 4 August 2015
Accepted: 25 November 2015
First Online: 8 January 2016
Competing interests
: Cédric Lemogne has received advisory panels or lecture fees from AstraZeneca, Bristol-Myers Squibb, Lundbeck, Pfizer, Pierre Fabre, Sanofi and Servier. Other authors have no conflicts of interest to declare.